PreludeDx™ Announces Partnership with America’s Choice Provider Network

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today that it has signed an agreement to become a provider in the America’s Choice Provider Network (ACPN). Under terms of the agreement, more than 30 million ACPN members from across the U.S. will have access and coverage for DCISionRT, the only DCIS Radio-Genomic test that offers personalized recurrence risk and radiation therapy treatment benefit for patients with ductal carcinoma in situ (DCIS).

“This is an important milestone for PreludeDx, clinicians and ACPN members,” said Daniel Forche, President and CEO of PreludeDx. “DCISionRT combines the latest innovations in molecular biology with artificial intelligence and machine learning to deliver the most advanced DCIS test available. For the first time, ACPN patients and their physicians will have personalized information to guide decisions about whether surgery alone or surgery with radiation therapy is appropriate.”

ACPN contracts directly with the healthcare providers of all types and specialties to establish simple and reliable healthcare access and reimbursement arrangements. Its independent network accessed by over 1,700 payers is one of the largest in the United States. With members in all 50 states, they have developed technology to deliver consistent healthcare transactions, simplified claims adjudication, reasonable reimbursement arrangements and reliable access.

“We are excited to partner with PreludeDx and provide their first-of-its-kind test for DCIS,” said Todd Breeden, CEO of ACPN. “We are committed to providing the latest technologies to our national provider network and DCISionRT is uniquely positioned to enable physicians to deliver precision medicine to DCIS patients, thus potentially improving patient care and reducing overall healthcare costs.”